NextCell Pharma publishes Interim Report 3 2021/2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2021 – May 31, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.Third quarter (2022-03-01 until 2022-05-31) ● Operating income amounted to 1 636 (906) TSEK. ● Operating result amounted to -9 307(-6 457) TSEK. ● Earnings per share* amounted to -0,